Literature DB >> 20514407

The immunoglobulin-like cell adhesion molecule hepaCAM is cleaved in the human breast carcinoma MCF7 cells.

Ting Zhang1, Mei C Moh, Lay H Lee, Shali Shen.   

Abstract

We previously reported the identification and characteristics of hepaCAM, a new immunoglobulin-like adhesion molecule. Frequently lost in diverse tumors, hepaCAM exhibits antiproliferative effects on cancer cells and promotes cell-extracellular matrix (ECM) interactions when re-expressed. Herein, we demonstrate for the first time that hepaCAM is cleaved in the human breast carcinoma MCF7 cells, generating a fragment containing mainly the cytoplasmic domain. The phorbol ester phorbol 12-myristate 13-acetate (PMA) did not affect the cleavage of hepaCAM. However, calcium-influx promoted hepaCAM cleavage independent of PKC. In addition, inhibitors of proteasome and cysteine proteases strongly suppressed the cleavage of hepaCAM, indicating the involvement of proteasome, calpain-1 and cathepsin B. Furthermore, we showed that functions of hepaCAM were impaired when the cytoplasmic domain was cleaved. The truncation mutant of hepaCAM failed to promote cell-ECM adhesion and migration, and lost the inhibitory effects on cell growth, suggesting a regulatory role of the cleavage in hepaCAM functions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514407

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer.

Authors:  Huanzhang Shao; Yinjie Gu; Junli Ding; Peihua Lu; Tingyan Ruan; Wenbin Lu
Journal:  Tumour Biol       Date:  2015-09-22

2.  HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.

Authors:  Zhongbo Du; Luo Li; Wei Sun; Xiao Wang; Yao Zhang; Zhixiong Chen; Mengjuan Yuan; Zhen Quan; Nanjing Liu; Yanni Hao; Ting Li; Jinhua Wang; Chunli Luo; Xiaohou Wu
Journal:  Int J Oncol       Date:  2018-04-12       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.